Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.68 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.68 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414974 | 1.00 | TXNRD1 (0.68) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL22804232 | 0.86 | TXNRD1 (0.50) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL11032479 | 0.79 | TXNRD1 (0.68) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL8403300 | 0.79 | TXNRD1 (0.68) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL7020999 | 0.78 | TXNRD1 (0.66) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL30771184 | 0.76 | TXNRD1 (0.51) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL10749290 | 0.76 | TXNRD1 (0.62) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL30330095 | 0.76 | CYP1A2 (0.51) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| SCHEMBL30330528 | 0.76 | TXNRD1 (0.50) | TXNRD1TXNRD3TXNRD2MAPTMEN1 | |
| Ethylene SCHEMBL10702288 | 0.76 | TXNRD1 (0.62) | TXNRD1TXNRD3TXNRD2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4442685-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | SPERMATECH AS (NO) | 2023-08-24 | — | — | US | disclosed |
| WO-2023104043-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 杭州和正医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116217566-A | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-1042294-B1 | HETEROCYCLIC CYTOTOXIC AGENTS | UNIV RUTGERS (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6486167-B1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-11-26 | — | — | US | disclosed |
| EP-1042294-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031067-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263155-A1 | 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY | NR5A1, NR1I3, NR5A2 | TXNRD1 445/4885TXNRD3 188/4885TXNRD2 680/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | TXNRD1 519/4885TXNRD3 1698/4885TXNRD2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.